Skip to main content
editorial
. 2014 Aug 8;98(11):1467–1469. doi: 10.1136/bjophthalmol-2014-305614

Table 1 .

Mean values at baseline and post-treatment (24 months) (number of letters on ETDRS chart)

Variable Ranibizumab (n=268)
mean (SD)
Bevacizumab (n=249)
mean (SD)
BCVA at baseline 62.9 (14.6) 62.0 (15.3)
BCVA at 24 months 67.8 (17.0) 66.1 (18.4)
Change from baseline 4.9 (15.0) 4.1 (13.5)

BCVA, Best Corrected Visual Acuity.